Literature DB >> 12671967

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.

Youla S Tsantrizos1, Gordon Bolger, Pierre Bonneau, Dale R Cameron, Nathalie Goudreau, George Kukolj, Steven R LaPlante, Montse Llinàs-Brunet, Herbert Nar, Daniel Lamarre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12671967     DOI： 10.1002/anie.200390347

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  20 in total

1.  A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.

Authors:  Nikolaus Schiering; Allan D'Arcy; Frederic Villard; Oliver Simic; Marion Kamke; Gaby Monnet; Ulrich Hassiepen; Dmitri I Svergun; Ruth Pulfer; Jörg Eder; Prakash Raman; Ursula Bodendorf
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.

Authors:  Christopher T Lemke; Nathalie Goudreau; Songping Zhao; Oliver Hucke; Diane Thibeault; Montse Llinàs-Brunet; Peter W White
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

3.  In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Authors:  Oliver Lenz; Thierry Verbinnen; Tse-I Lin; Leen Vijgen; Maxwell D Cummings; Jimmy Lindberg; Jan Martin Berke; Pascale Dehertogh; Els Fransen; Annick Scholliers; Katrien Vermeiren; Tania Ivens; Pierre Raboisson; Michael Edlund; Susan Storm; Lotta Vrang; Herman de Kock; Gregory C Fanning; Kenneth A Simmen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

4.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

5.  Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.

Authors:  Ashley N Matthew; Jacqueto Zephyr; Caitlin J Hill; Muhammad Jahangir; Alicia Newton; Christos J Petropoulos; Wei Huang; Nese Kurt-Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2017-06-19       Impact factor: 7.446

6.  Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.

Authors:  Jeff A O'Meara; Christopher T Lemke; Cédrickx Godbout; George Kukolj; Lisette Lagacé; Benoît Moreau; Diane Thibeault; Peter W White; Montse Llinàs-Brunet
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

7.  Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.

Authors:  Lynne Cregar-Hernandez; Guan-Sheng Jiao; Alan T Johnson; Axel T Lehrer; Teri Ann S Wong; Stephen A Margosiak
Journal:  Antivir Chem Chemother       Date:  2011-05-12

8.  Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Authors:  Hongmei Mo; Liangjun Lu; Tami Pilot-Matias; Ron Pithawalla; Rubina Mondal; Sherie Masse; Tatyana Dekhtyar; Teresa Ng; Gennadiy Koev; Vincent Stoll; Kent D Stewart; John Pratt; Pam Donner; Todd Rockway; Clarence Maring; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

9.  Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.

Authors:  Akbar Ali; Cihan Aydin; Reinhold Gildemeister; Keith P Romano; Hong Cao; Ayşegül Ozen; Djade Soumana; Alicia Newton; Christos J Petropoulos; Wei Huang; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2013-05-01       Impact factor: 5.100

10.  Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line.

Authors:  Samir Ali; Charles Pellerin; Daniel Lamarre; George Kukolj
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.